Chemotherapy plus radiation for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) given together with radiation therapy for locally advanced esophageal cancer. It aims to see if this treatment is safe and effective, potentially offering a new option for patients who cannot have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma that has not spread to distant organs.
- You have not received any previous treatment (surgery, chemotherapy, or radiation) for this cancer.
- You are able to care for yourself (fully active or slightly restricted) and expected to live at least 3 more months.
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You agree to use effective birth control during the study and for 6 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.